Your browser doesn't support javascript.
loading
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Attard, Gerhardt; Murphy, Laura; Clarke, Noel W; Sachdeva, Ashwin; Jones, Craig; Hoyle, Alex; Cross, William; Jones, Robert J; Parker, Christopher C; Gillessen, Silke; Cook, Adrian; Brawley, Chris; Gilson, Clare; Rush, Hannah; Abdel-Aty, Hoda; Amos, Claire L; Murphy, Claire; Chowdhury, Simon; Malik, Zafar; Russell, J Martin; Parkar, Nazia; Pugh, Cheryl; Diaz-Montana, Carlos; Pezaro, Carmel; Grant, Warren; Saxby, Helen; Pedley, Ian; O'Sullivan, Joe M; Birtle, Alison; Gale, Joanna; Srihari, Narayanan; Thomas, Carys; Tanguay, Jacob; Wagstaff, John; Das, Prantik; Gray, Emma; Alzouebi, Mymoona; Parikh, Omi; Robinson, Angus; Montazeri, Amir H; Wylie, James; Zarkar, Anjali; Cathomas, Richard; Brown, Michael D; Jain, Yatin; Dearnaley, David P; Mason, Malcolm D; Gilbert, Duncan; Langley, Ruth E; Millman, Robin.
Afiliação
  • Attard G; Cancer Institute, University College London, London, UK; University College London Hospitals, London, UK. Electronic address: g.attard@ucl.ac.uk.
  • Murphy L; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Clarke NW; Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
  • Sachdeva A; Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
  • Jones C; Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
  • Hoyle A; Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
  • Cross W; St James's University Hospital, Leeds, UK.
  • Jones RJ; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.
  • Parker CC; Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
  • Gillessen S; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; CH and Universita della Svizzera Italiana, Lugano, Switzerland.
  • Cook A; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Brawley C; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Gilson C; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Rush H; Medical Research Council Clinical Trials Unit, University College London, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Abdel-Aty H; Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
  • Amos CL; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Murphy C; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Chowdhury S; Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Malik Z; Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK.
  • Russell JM; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Parkar N; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Pugh C; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Diaz-Montana C; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Pezaro C; Singleton Hospital, Swansea, UK.
  • Grant W; Gloucestershire Oncology Centre, Cheltenham, UK.
  • Saxby H; Torbay and South Devon NHS Foundation Trust, Torbay, UK.
  • Pedley I; Northern Centre for Cancer Care, Newcastle upon Tyne, UK.
  • O'Sullivan JM; Queen's University Belfast, Belfast, UK.
  • Birtle A; Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK.
  • Gale J; Queen Alexandra Hospital, Portsmouth, UK.
  • Srihari N; Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK.
  • Thomas C; Kent Oncology Centre, Maidstone, UK.
  • Tanguay J; Velindre Cancer Centre, Cardiff, UK.
  • Wagstaff J; Singleton Hospital, Swansea, UK.
  • Das P; Royal Derby Hospital, Derby, UK.
  • Gray E; Yeovil District Hospital NHS Foundation Trust, Yeovil, UK.
  • Alzouebi M; Weston Park Hospital, Sheffield, UK.
  • Parikh O; East Lancashire Hospitals NHS Trust, Preston, UK.
  • Robinson A; Royal Sussex County Hospital, Brighton, UK.
  • Montazeri AH; Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK.
  • Wylie J; Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
  • Zarkar A; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Cathomas R; Division of Oncology and Hematology, Cantonal Hospital Graubünden, Chur, Switzerland; Swiss Group for Clinical Cancer Research, Bern, Switzerland.
  • Brown MD; Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
  • Jain Y; Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
  • Dearnaley DP; Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
  • Mason MD; Cardiff University, Cardiff, UK.
  • Gilbert D; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Langley RE; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Millman R; Medical Research Council Clinical Trials Unit, University College London, London, UK.
Lancet Oncol ; 24(5): 443-456, 2023 05.
Article em En | MEDLINE | ID: mdl-37142371
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Neoplasias de Próstata Resistentes à Castração Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Neoplasias de Próstata Resistentes à Castração Idioma: En Ano de publicação: 2023 Tipo de documento: Article